PPMD's Response to PTC Announcement of EMFLAZA (deflazacort) Pricing & Access

Today, PTC Therapeutics provided a community update on EMFLAZA (deflazacort) which they acquired earlier in the year from Marathon Pharmaceuticals. PPMD will continue to monitor and remain engaged in the access environment in order to understand the impact of every new approval, including EMFLAZA, and will update our online Access Resource as information becomes available.
Source: Parent Project Muscular Dystrophy - Category: Neurology Source Type: news